Fenótipos aberrantes em leucemia mieloide aguda e sua relação com prognóstico e sobrevida : uma revisão sistemática

Abstract

Acute myeloid leukemia is a hematologic malignancy highly associated with poor prognosis and low survival rate. Aberrant phenotypes detected by immunophenotyping have been associated with a worse clinical course of the disease, specially, when related with prognosis and survival rate. The aim of this systematic review was to evaluate the influence of aberrant markers in prognosis and survival of acute myeloid leukemia. Materials and methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic review of PubMed, Scopus, Science Direct, Web of Science and Cochrane Library was carried out through 1998 to 2016. Results: We included 16 studies on this systematic review, which the aberrant phenotype expression of 30 markers were detected by flow cytometry using samples of 2,000 patients. From all those, the expression of nine aberrant markers were related to prognosis, and five had shown negative impact on prognosis in AML. This systematic review studied the following markers CD7, CD82, CD34, CD19, CD56, CD98, CD90, CD123, and CD15. Conclusions: The prognosis implication of aberrant antigen remains controversy and new studies are essential for a better understanding of leukemia features. In order to lead to higher rates of complete remission, the development of a target therapy is becoming prominent.